stockrowAlnylam Pharmaceuticals, Inc.
ALNY Healthcare Biotechnology
Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.
- Revenue
- +16.7%
- EPS
- +747.6%
- Free cash flow
- −4.76%
- Total debt
- −2.66%
Quarter to September 2026, against a year earlier
Follow ALNY
Alert me
Alnylam Pharmaceuticals, Inc. (ALNY) Net income
Alnylam Pharmaceuticals, Inc.'s net income for fiscal 2025 was $313.7M, compared with −$278.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was $2.6B. Over the past ten years it has ranged from −$1.1B (fiscal 2022) to $313.7M (fiscal 2025) — the current reading is the highest in ten years. Net income has risen for 3 consecutive fiscal years. Alnylam Pharmaceuticals, Inc. ranks 3rd of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $313.7M | — |
| FY2024 | −$278.2M | — |
| FY2023 | −$440.2M | — |
| FY2022 | −$1.1B | — |
| FY2021 | −$852.8M | — |
| FY2020 | −$858.3M | — |
| FY2019 | −$886.1M | — |
| FY2018 | −$761.5M | — |
| FY2017 | −$490.9M | — |
| FY2016 | −$410.1M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $2.2B | 1,217.58% |
| Jun 2026 | $164.5M | (20.15%) |
| Mar 2026 | $206.0M | 84.67% |
| Dec 2025 | $111.5M | (61.89%) |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. | $2.6B |
| EXEL Exelixis, Inc. compare | $885.1M |
| ASND Ascendis Pharma A/S compare | $865.9M |
| INCY Incyte Corporation compare | $403.4M |
| JAZZ Jazz Pharmaceuticals PLC compare | $206.0M |
| ROIV Roivant Sciences Ltd. compare | −$414.6M |
| BBIO BridgeBio Pharma, Inc. compare | −$577.6M |
| INSM Insmed, Inc. compare | −$605.6M |
| BNTX BioNTech SE Sponsored ADR compare | −$1.6B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on ALNY
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement